Advantage plans do a better job than standalone Part D policies, albeit with important gap ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

Please provide your email address to receive an email when new articles are posted on . Demographic factors were significantly associated with slower or faster initiation of b/ts DMARDs for RA.

Please provide your email address to receive an email when new articles are posted on . Sustained DMARD-free remission “does not seem attainable” for patients with RA requiring biological DMARDs, but ...

The treat-to-target approach represented a stepped-up model for chronic disease management that only became possible when the available therapies showed the potential for disease remission. The ...

Nonadherence to DMARDs in RA varies widely, with rates from 1.5% to 100% across different studies and DMARD classes. The review identified 31 unique nonadherence measures, with indirect methods like ...

Introduction Interstitial lung disease (ILD) is a serious extra-articular manifestation of rheumatoid arthritis (RA) associated with increased morbidity and mortality. The pulmonary safety of biologic ...

Use of a tumor necrosis factor inhibitor (TNFi) or triple therapy with conventional, synthetic disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis have similar beneficial effects ...

Understanding the type of arthritis, its causes, and management options is the first step toward living well with the condition.